A Phase 1, Open-label Study in Two Parts, Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of CCW702 in Patients With Metastatic, Castration Resistant Prostate Adenocarcinoma
Latest Information Update: 17 May 2023
At a glance
- Drugs CCW 702 (Primary)
- Indications Adenocarcinoma; Brain metastases; Prostate cancer
- Focus Adverse reactions; First in man; Therapeutic Use
Most Recent Events
- 17 May 2023 Status changed from active, no longer recruiting to discontinued.
- 29 Sep 2022 Status changed from recruiting to active, no longer recruiting.
- 08 Jun 2021 Trial design presented at the 57th Annual Meeting of the American Society of Clinical Oncology.